News AbbVie bullish on Humira and near-term pipeline Sales of Humira could peak above $18 billion - CEO
News Amjevita, first Humira biosimilar approved – but no launch y... Amgen's biosimilar is ready to go, but AbbVie believes it can delay until 2022
News AbbVie waits on data from Humira successor Ablynx's vobarilizumab seen as key should Humira sales fall.
News Biogen eyeing big-selling biosimilars as MS drug fails Gamble on opicinumab looks unlikely to pay off.
News Amgen biosimilar stands up against Humira Amgen's biosimilar candidate ABP 501 has shown comparable results in phase III, measured against AbbVie's blockbuster Humira (adalimumab), for patients with moderate-to-severe plaque psoria
News Halozyme abandons its €2bn pursuit of Evotec Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been unwilling to engage with negotiations
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
